Literature DB >> 24043801

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

Joshua A Horwitz1, Ariel Halper-Stromberg, Hugo Mouquet, Alexander D Gitlin, Anna Tretiakova, Thomas R Eisenreich, Marine Malbec, Sophia Gravemann, Eva Billerbeck, Marcus Dorner, Hildegard Büning, Olivier Schwartz, Elena Knops, Rolf Kaiser, Michael S Seaman, James M Wilson, Charles M Rice, Alexander Ploss, Pamela J Bjorkman, Florian Klein, Michel C Nussenzweig.   

Abstract

Effective control of HIV-1 infection in humans is achieved using combinations of antiretroviral therapy (ART) drugs. In humanized mice (hu-mice), control of viremia can be achieved using either ART or by immunotherapy using combinations of broadly neutralizing antibodies (bNAbs). Here we show that treatment of HIV-1-infected hu-mice with a combination of three highly potent bNAbs not only resulted in complete viremic control but also led to a reduction in cell-associated HIV-1 DNA. Moreover, lowering the initial viral load by coadministration of ART and immunotherapy enabled prolonged viremic control by a single bNAb after ART was withdrawn. Similarly, a single injection of adeno-associated virus directing expression of one bNAb produced durable viremic control after ART was terminated. We conclude that immunotherapy reduces plasma viral load and cell-associated HIV-1 DNA and that decreasing the initial viral load enables single bNAbs to control viremia in hu-mice.

Entities:  

Keywords:  CD4bs; glycan; gp160

Mesh:

Substances:

Year:  2013        PMID: 24043801      PMCID: PMC3799352          DOI: 10.1073/pnas.1315295110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

Authors:  F García; M Plana; C Vidal; A Cruceta; W A O'Brien; G Pantaleo; T Pumarola; T Gallart; J M Miró; J M Gatell
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

Authors:  P R Harrigan; M Whaley; J S Montaner
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

3.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

4.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.

Authors:  J A Bartlett; R DeMasi; J Quinn; C Moxham; F Rousseau
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

Review 5.  Prospects for an HIV vaccine: leading B cells down the right path.

Authors:  Susan Moir; Angela Malaspina; Anthony S Fauci
Journal:  Nat Struct Mol Biol       Date:  2011-12-05       Impact factor: 15.369

6.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Authors:  Alexandra Trkola; Herbert Kuster; Peter Rusert; Beda Joos; Marek Fischer; Christine Leemann; Amapola Manrique; Michael Huber; Manuela Rehr; Annette Oxenius; Rainer Weber; Gabriela Stiegler; Brigitta Vcelar; Hermann Katinger; Leonardo Aceto; Huldrych F Günthard
Journal:  Nat Med       Date:  2005-05-08       Impact factor: 53.440

7.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.

Authors:  Stefan Baenziger; Roxane Tussiwand; Erika Schlaepfer; Luca Mazzucchelli; Mathias Heikenwalder; Michael O Kurrer; Silvia Behnke; Joachim Frey; Annette Oxenius; Helen Joller; Adriano Aguzzi; Markus G Manz; Roberto F Speck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

9.  CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.

Authors:  Cécile Goujard; Mojgan Bonarek; Laurence Meyer; Fabrice Bonnet; Marie-Laure Chaix; Christiane Deveau; Martine Sinet; Julie Galimand; Jean-François Delfraissy; Alain Venet; Christine Rouzioux; Philippe Morlat
Journal:  Clin Infect Dis       Date:  2006-01-24       Impact factor: 9.079

10.  Inefficient human immunodeficiency virus replication in mobile lymphocytes.

Authors:  Marion Sourisseau; Nathalie Sol-Foulon; Françoise Porrot; Fabien Blanchet; Olivier Schwartz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more
  153 in total

Review 1.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Authors:  Ariel Halper-Stromberg; Michel C Nussenzweig
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

2.  Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice.

Authors:  Anne-Sophie Kuhlmann; Kevin G Haworth; Isaac M Barber-Axthelm; Christina Ironside; Morgan A Giese; Christopher W Peterson; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

Review 3.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

4.  Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.

Authors:  Hongru Li; Chati Zony; Ping Chen; Benjamin K Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

5.  Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Authors:  Nina C Flerin; Ariola Bardhi; Jian Hua Zheng; Maria Korom; Joy Folkvord; Colin Kovacs; Erika Benko; Ronald Truong; Talia Mota; Elizabeth Connick; R Brad Jones; Rebecca M Lynch; Harris Goldstein
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

Authors:  Ming Sun; Craig S Pace; Xin Yao; Faye Yu; Neal N Padte; Yaoxing Huang; Michael S Seaman; Qihan Li; David D Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

8.  Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.

Authors:  Yanling Wu; Jing Xue; Chunyu Wang; Wei Li; Lili Wang; Weizao Chen; Ponraj Prabakaran; Desheng Kong; Yujia Jin; Dan Hu; Yulu Wang; Cheng Lei; Diao Yu; Chao Tu; Ariola Bardhi; Igor Sidorov; Liying Ma; Harris Goldstein; Chuan Qin; Lu Lu; Shibo Jiang; Dimiter S Dimitrov; Tianlei Ying
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Authors:  Ching-Lan Lu; Dariusz K Murakowski; Stylianos Bournazos; Till Schoofs; Debolina Sarkar; Ariel Halper-Stromberg; Joshua A Horwitz; Lilian Nogueira; Jovana Golijanin; Anna Gazumyan; Jeffrey V Ravetch; Marina Caskey; Arup K Chakraborty; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

10.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.